-

BeiGene to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING--(BUSINESS WIRE)--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will participate in two upcoming investor conferences:

  • The 6th Annual Cowen IO Next Virtual Conference on Friday, November 11, at 9:40 a.m. (ET); and
  • The 13th Annual Jefferies Global Healthcare Conference in London on Wednesday, November 16 at 11:25 a.m. (ET).

A live webcast can be accessed from the investors section of BeiGene’s websites at https://ir.beigene.com, https://hkexir.beigene.com and https://sseir.beigene.com. An archived replay will be available for 90 days following the event.

About BeiGene
BeiGene is a global biotechnology company that is developing and commercializing innovative and affordable oncology medicines to improve treatment outcomes and access for far more patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of more than 9,000 colleagues spans five continents, with administrative offices in Beijing, China; Cambridge, U.S.; and Basel, Switzerland. To learn more about BeiGene, please visit www.beigene.com and follow us on Twitter at @BeiGeneGlobal.

Contacts

Investor
Kevin Mannix
+1-857-302-5189
ir@beigene.com

Media
Kyle Blankenship
+1 667-351-5176
media@beigene.com

BeiGene

NASDAQ:ONC
Details
Headquarters: San Carlos, CA & Basel, Switzerland, California
CEO: John V. Oyler
Employees: 11,000+
Organization: PUB
Revenues: $3.8B USD (2024)

Release Versions

Contacts

Investor
Kevin Mannix
+1-857-302-5189
ir@beigene.com

Media
Kyle Blankenship
+1 667-351-5176
media@beigene.com

More News From BeiGene

BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will outline the pillars of its growing global oncology leadership during its presentation today at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. John V. Oyler, Co-Founder, Chairman, and CEO at BeOne, will highlight the Company’s transformative leadership in treating B-cell malignancies. The presentation will feature BRUKINSA®, the global leader amo...

ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). These data, includin...

BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, with a presentation at 7:30 am PST. Live webcasts of these events can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com, https://hkexir.beonemedicines.com, https://sseir.beonemedicines.com. Archived replays...
Back to Newsroom